Prof. Zhao Peiquan

Academic Profile

Prof. Zhao Peiquan leads the retinoblastoma team at Xinhua Hospital — the world's largest intra-arterial chemotherapy (IAC) center for this disease — achieving survival above 99% and eye preservation around 80%. His group publishes in JAMA Ophthalmology and Ophthalmology and offers families world-class eye-saving treatment with structured long-term follow-up.

Appointments & Honors

• Runs the world's largest retinoblastoma intra-arterial chemotherapy center — survival >99%, eye preservation ~80%
• Published in JAMA Ophthalmology & Ophthalmology; identified novel RB-associated genes (JAG1, CTNNA1)
• Recipient, National Maternal & Child Health Science & Technology Award; 58 SCI papers

Appointments

• Professor of Ophthalmology; Lead, Retinoblastoma Program, Xinhua Hospital
• Head of the world's largest retinoblastoma intra-arterial chemotherapy center
• National Maternal & Child Health Science & Technology Award recipient

Academic Achievements

• Built the world's largest retinoblastoma IAC program — survival >99%, eye preservation ~80%
• Published 58 SCI papers including JAMA Ophthalmology and Ophthalmology
• Identified novel retinoblastoma-associated genes (JAG1, CTNNA1)
• National referral center for advanced intraocular retinoblastoma

Selected Publications

• Bilateral conversion risk in unilateral retinoblastoma

  JAMA Ophthalmology · 2025 · Corresponding author

• Superselective intra-arterial chemotherapy for advanced intraocular retinoblastoma: long-term outcomes

  Ophthalmology · 2021 · Corresponding author